Worth Venture Partners’s Agile Therapeutics AGRX Stock Holding History

Worth Venture Partners’s Portfolio AGRX Stock Details AGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-82	Closed	-$195K	–	112
2019 Q3	$195K	Buy	+82	New	+$202K	0.11%	71

Other funds holding AGRX

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

EAM Investors Solana Beach, California $1.12B AUM 390.6% 1-Year Est. Return

Worth Venture Partners's AGRX Position: Q4 2019 in Review

Worth Venture Partners sold out of Agile Therapeutics (AGRX) in Q4 2019, closing a stake of 82 shares — an estimated $195K sold.

Worth Venture Partners first reported a position in AGRX in Q3 2019 and held it in 1 quarter. The position peaked at $195K in Q3 2019. 46 funds tracked by Wall St. Rank hold AGRX as of Q4 2019.

Worth Venture Partners reported no remaining Agile Therapeutics position as of Q4 2019 after selling out during the quarter.
Worth Venture Partners sold 82 Agile Therapeutics shares in Q4 2019, an estimated $195K.
Worth Venture Partners first reported a position in Agile Therapeutics in Q3 2019 and held it in 1 quarter.
Worth Venture Partners's Agile Therapeutics position peaked at $195K in Q3 2019.
46 funds tracked by Wall St. Rank held Agile Therapeutics as of Q4 2019.

Based on Worth Venture Partners's 13F filing for Q4 2019, filed 14 Feb 2020.